Tea polyphenol epigallocatechin-3-gallate inhibits cell proliferation in a patient-derived triple-negative breast cancer xenograft mouse model via inhibition of proline-dehydrogenase-induced effects
| Autor: | Tzu Chun Cheng, Hui Wen Chang, Wen Jui Lee, Yuan Soon Ho, You Cheng Liao, Shih Hsin Tu, Li Cheng Lin, Chia Lang Fang, Ching Chuan Kuo, Li Ching Chen, Yun Yen |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Pharmacology
Proline Tea Chemistry Cell growth Polyphenols Triple Negative Breast Neoplasms Gallate Catechin Disease Models Animal Mice Proline dehydrogenase Polyphenol Cell Line Tumor Cancer research Proline Oxidase Animals Heterografts Humans Triple-negative breast cancer Tumor xenograft Food Science Cell Proliferation |
| Zdroj: | Journal of food and drug analysis. 29(1) |
| ISSN: | 2224-6614 |
| Popis: | Triple-negative breast cancers (TNBCs) lack specific targeted therapy options and have evolved into highly chemo-resistant tumors that metastasize to multiple organs. The present study demonstrated that the proline dehydrogenase (PRODH) mRNA level in paired (tumor vs. normal) human breast tissue samples (n=234) was 6.6-fold greater than normal cells (*p=0.021). We established stable PRODH-overexpressing TNBC (HS578T) cells, and the malignant phenotypes were evaluated using soft agar colony formation and Transwell migration assays. The results demonstrated that PRODH induced epithelial-mesenchymal transition in cancer cells and increased cell proliferation. The present study found that the tea polyphenol epigallocatechin-3-gallate (EGCG) significantly inhibited PRODH and its regulated proteins, such as alpha-smooth muscle actin (alpha-SMA) expression in TNBC cells. These findings support the targeting of the PRODH signaling pathway as a potential therapeutic strategy in preventing cancer cell metastasis. The patient-derived xenograft (PDX) mouse model is highly relevant to real human tumor growth. We established a TNBC-PDX (F4, n=4 in each group)mouse model. The PDX mice were treated with EGCG (50 mg/kg), and the results indicated that EGCG significantly inhibited PDX tumor growth (*p = 0.013). These experiments provide additional evidence to evaluate the antitumor effects of EGCG-induced PRODH inhibition for clinical therapeutic application, especially in TNBC patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|